France's Abivax 2025 net loss widens on higher R&D and G&A costs

Abivax SA

23/03/2026 20:18

Overview

France clinical-stage biotech's 2025 net loss widened, reflecting higher R&D and G&A expenses

Company ended 2025 with €530.4 mln in cash, cash equivalents and short-term investments

Outlook

Abivax expects topline results from ABTECT-UC Phase 3 trial in late Q2 2026

Company plans NDA submission for obefazimod in UC in Q4 2026, subject to positive data

Abivax projects cash runway into Q4 2027 based on current operating assumptions

Result Drivers

R&D SPENDING - Higher R&D expenses, partly driven by increased clinical trial activity for obefazimod in ulcerative colitis and Crohn's disease

G&A COSTS - General and administrative expenses rose mainly due to higher personnel costs, including employer taxes and social contributions linked to an increase in the company’s share price

S&M EXPENSES - Sales and marketing expenses declined as one-time rebranding costs in 2024 were not repeated, partially offset by higher personnel costs

Company press release: ID:nGNX2LL2xM

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-EUR 336.1 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Abivax SA is €134.00, about 32.4% above its March 23 closing price of €101.20

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)